NO942864L - Benzokondenserte 5-ringheterocykler, fremgangsmåte for fremstilling derav, deres anvendelse som medikament, deres anvendelse som diagnostikum samt medikament inneholdene disse - Google Patents

Benzokondenserte 5-ringheterocykler, fremgangsmåte for fremstilling derav, deres anvendelse som medikament, deres anvendelse som diagnostikum samt medikament inneholdene disse

Info

Publication number
NO942864L
NO942864L NO942864A NO942864A NO942864L NO 942864 L NO942864 L NO 942864L NO 942864 A NO942864 A NO 942864A NO 942864 A NO942864 A NO 942864A NO 942864 L NO942864 L NO 942864L
Authority
NO
Norway
Prior art keywords
drug
benzo
diagnostic
condensed
preparation
Prior art date
Application number
NO942864A
Other languages
English (en)
Other versions
NO942864D0 (no
NO301584B1 (no
Inventor
Hans-Jochen Lang
Andreas Weichert
Jan-Robert Schwark
Wolfgang Scholz
Udo Albus
Peter Crause
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE4326005A external-priority patent/DE4326005A1/de
Priority claimed from DE19944414316 external-priority patent/DE4414316A1/de
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of NO942864D0 publication Critical patent/NO942864D0/no
Publication of NO942864L publication Critical patent/NO942864L/no
Publication of NO301584B1 publication Critical patent/NO301584B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C07D235/32—Benzimidazole-2-carbamic acids, unsubstituted or substituted; Esters thereof; Thio-analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/18—Benzotriazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/86—Benzo [b] furans; Hydrogenated benzo [b] furans with an oxygen atom directly attached in position 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D333/70—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
NO942864A 1993-08-03 1994-08-02 Benzokondenserte 5-ringheterocykler, deres anvendelse til fremstilling av medikament og diagnostikum, samt medikamenter inneholdende disse NO301584B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4326005A DE4326005A1 (de) 1993-08-03 1993-08-03 Benzokondensierte 5-Ringheterocyclen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, ihre Verwendung als Diagnostikum, sowie sie enthaltendes Medikament
DE19944414316 DE4414316A1 (de) 1994-04-25 1994-04-25 Benzokondensierte 5-Ringheterocyclen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, ihre Verwendung als Diagnostikum, sowie sie enthaltendes Medikament

Publications (3)

Publication Number Publication Date
NO942864D0 NO942864D0 (no) 1994-08-02
NO942864L true NO942864L (no) 1995-02-06
NO301584B1 NO301584B1 (no) 1997-11-17

Family

ID=25928286

Family Applications (1)

Application Number Title Priority Date Filing Date
NO942864A NO301584B1 (no) 1993-08-03 1994-08-02 Benzokondenserte 5-ringheterocykler, deres anvendelse til fremstilling av medikament og diagnostikum, samt medikamenter inneholdende disse

Country Status (11)

Country Link
EP (1) EP0639573A1 (no)
JP (1) JPH07145149A (no)
KR (2) KR100343292B1 (no)
CN (1) CN1118347A (no)
AU (1) AU682371B2 (no)
CA (1) CA2129301A1 (no)
FI (1) FI943579A (no)
HU (1) HU218790B (no)
IL (1) IL110503A (no)
NO (1) NO301584B1 (no)
NZ (1) NZ264130A (no)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6169107B1 (en) 1993-04-28 2001-01-02 Sumitomo Pharmaceutical Co., Ltd. Indoloylguanidine derivatives
CA2121391A1 (en) * 1993-04-28 1994-10-29 Atsuyuki Kojima Indoloylguanidine derivatives
DE4412334A1 (de) * 1994-04-11 1995-10-19 Hoechst Ag Substituierte N-Heteroaroylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
AU683552B2 (en) * 1994-04-11 1997-11-13 Chugai Seiyaku Kabushiki Kaisha 4,6-DI-t-butyl-2,3-dihydrobenzothiophene derivative
CA2160600A1 (en) * 1994-10-18 1996-04-19 Masahumi Kitano Indoloylguanidine derivatives
US5834466A (en) * 1994-12-22 1998-11-10 The Regents Of The University Of California Method for protecting of heart by limiting metabolic and ionic abnormalities developed during ischemia, following ischemia or resulting from ischemia
ATE183498T1 (de) * 1995-04-18 1999-09-15 Hoechst Ag Substituierte indenoylguanidines mit antiarrhythmischer und cardioprotektiver wirkung
DE19540995A1 (de) * 1995-11-03 1997-05-07 Hoechst Ag Substituierte Sulfonimidamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19542306A1 (de) * 1995-11-14 1997-05-15 Hoechst Ag Sulfonylamino-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
PL316439A1 (en) * 1995-11-20 1997-05-26 Hoechst Ag Novel substituted derivatives of benzoyloguanidine, method of obtaining them, their application in production of pharmaceutic and diagnostic agents and pharmaceutic agent as such
DE19546736A1 (de) * 1995-12-14 1997-06-19 Hoechst Ag Substituierte Chromanylsulfonyl(thio)harnstoffe, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung pharmazeutischer Präparate
DE19548708A1 (de) * 1995-12-23 1997-06-26 Merck Patent Gmbh Cyclische Sulfone
DE19548812A1 (de) * 1995-12-27 1997-07-03 Hoechst Ag Verwendung von Inhibitoren des zellulären Na·+·/H·+·-Exchangers (NHE) zur Herstellung eines Medikaments zur Atemstimulation
CA2195697A1 (en) * 1996-02-02 1997-08-03 Masahumi Kitano Novel substituted guanidine derivatives, process for production thereof, and pharmaceutical uses thereof
AU2193797A (en) * 1996-03-01 1997-09-16 Chiron Corporation Delivery of therapeutic agents to the prostate
JP2002502414A (ja) * 1997-06-02 2002-01-22 藤沢薬品工業株式会社 細胞中のＮａ▲上＋▼／Ｈ▲上＋▼交換の阻害剤としてのグアニジン誘導体
GB9716657D0 (en) * 1997-08-07 1997-10-15 Zeneca Ltd Chemical compounds
US6011059A (en) * 1997-12-24 2000-01-04 Bristol-Myers Squibb Company Acyl guanidine sodium/proton exchange inhibitors and method
US6160134A (en) * 1997-12-24 2000-12-12 Bristol-Myers Squibb Co. Process for preparing chiral cyclopropane carboxylic acids and acyl guanidines
CA2260499A1 (en) * 1998-01-29 1999-07-29 Sumitomo Pharmaceuticals Company Limited Pharmaceutical compositions for the treatment of ischemic brain damage
GB9803226D0 (en) 1998-02-17 1998-04-08 Zeneca Ltd Chemical compounds
KR20030083004A (ko) * 1998-02-27 2003-10-23 화이자 프로덕츠 인크. 허혈 치료용 ｎ-[(치환된 5원 디아자 이불포화고리)카르보닐] 구아니딘 유도체
CN101284865A (zh) 1998-11-05 2008-10-15 富山化学工业株式会社 新型化合物及其医药用途
GB9902461D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902452D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902459D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902455D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
GB9902453D0 (en) 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
WO2000064445A1 (en) 1999-04-23 2000-11-02 Bristol-Myers Squibb Company Bicyclic acyl guanidine sodium/proton exchange inhibitors and method
EP1238971A4 (en) * 1999-12-16 2003-02-26 Sumitomo Pharma SUBSTITUTED GUANIDINE DERIVATIVES
GB0000625D0 (en) 2000-01-13 2000-03-01 Zeneca Ltd Chemical compounds
WO2002051805A1 (de) 2000-12-27 2002-07-04 Bayer Aktiengesellschaft Indol-derivate
DE10163239A1 (de) * 2001-12-21 2003-07-10 Aventis Pharma Gmbh Substituierte Imidazolidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie enthaltendes Medikament
TWI350285B (en) 2002-03-13 2011-10-11 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
FR2842526B1 (fr) * 2002-07-16 2007-07-13 Aventis Pharma Sa Compositions pharmaceutiques contenant un derive de 3-guanidinocarbonyl-1-heteroaryl-indole, procede de preparation a titre de medicaments
FR2842525B1 (fr) * 2002-07-16 2005-05-13 Aventis Pharma Sa Derives de 3-guanidinocarbonyl-1-heteroaryl-indole, procede de preparation a titre de medicaments et compositions pharmaceutiques les renfermant
US7141600B2 (en) 2003-04-15 2006-11-28 The Regents Of The University Of California Small molecule inhibition of a PDZ-domain interaction
FR2856062B1 (fr) * 2003-06-12 2005-11-11 Aventis Pharma Sa Derives 3-guanidinocarbonyl-heterocycle, procede de preparation et intermediaires de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
KR20070028553A (ko) 2004-06-18 2007-03-12 바이올리폭스 에이비 염증 치료에 유용한 인돌
CN101014568A (zh) 2004-07-01 2007-08-08 加利福尼亚大学董事会 抑制pdz－结构域相互作用的小分子
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7645881B2 (en) 2004-07-22 2010-01-12 Ptc Therapeutics, Inc. Methods for treating hepatitis C
CA2594221C (en) * 2004-12-27 2010-09-21 Yuyu Inc. Benzothiophen-2-carbonylguanidine derivatives, preparation thereof, and pharmaceutical composition containing the same
WO2006077366A1 (en) 2005-01-19 2006-07-27 Biolipox Ab Indoles useful in the treatment of inflammation
KR100644385B1 (ko) * 2005-02-25 2006-11-10 동양수기산업(주) 흡입식 슬러지 수집기
US8076348B2 (en) 2005-08-08 2011-12-13 Astellas Pharma Inc. Acylguanidine derivative or salt thereof
TWI387592B (zh) 2005-08-30 2013-03-01 Novartis Ag 經取代之苯并咪唑及其作為與腫瘤形成相關激酶之抑制劑之方法
KR20080085014A (ko) 2005-12-09 2008-09-22 에프. 호프만-라 로슈 아게 비만 치료에 유용한 트라이사이클릭 아마이드 유도체
UA95788C2 (en) 2005-12-15 2011-09-12 Ф. Хоффманн-Ля Рош Аг Fused pyrrole derivatives
US7645752B2 (en) 2006-01-13 2010-01-12 Wyeth Llc Sulfonyl substituted 1H-indoles as ligands for the 5-hydroxytryptamine receptors
CN101384550B (zh) * 2006-02-20 2011-08-31 安斯泰来制药株式会社 酰胺衍生物或其盐
EP1988075B1 (en) 2006-02-20 2012-01-25 Astellas Pharma Inc. Pyrrole derivative or salt thereof
SG177918A1 (en) * 2006-12-26 2012-02-28 Lantheus Medical Imaging Inc Ligands for imaging cardiac innervation
MX336731B (es) 2010-01-28 2016-01-28 Harvard College Composiciones y metodos para potenciar la actividad de proteasoma.
US8759535B2 (en) 2010-02-18 2014-06-24 High Point Pharmaceuticals, Llc Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
ES2724531T3 (es) 2011-05-12 2019-09-11 Proteostasis Therapeutics Inc Reguladores de proteostasis
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
US10093640B2 (en) 2012-09-21 2018-10-09 Vanderbilt University Substituted benzofuran, benzothiophene and indole MCL-1 inhibitors
WO2014116228A1 (en) 2013-01-25 2014-07-31 President And Fellows Of Harvard College Usp14 inhibitors for treating or preventing viral infections
US9394285B2 (en) 2013-03-15 2016-07-19 Pfizer Inc. Indole and indazole compounds that activate AMPK
EP3038618B1 (en) 2013-08-28 2020-10-14 Vanderbilt University Substituted indole mcl-1 inhibitors
WO2015073528A1 (en) 2013-11-12 2015-05-21 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
EP3122353B1 (en) 2014-03-27 2020-10-28 Vanderbilt University Substituted indole mcl-1 inhibitors
HUE055262T2 (hu) 2014-08-11 2021-11-29 Angion Biomedica Corp Citokróm P450 inhibitorok és ezek alkalmazásai
CN105884675A (zh) * 2014-09-24 2016-08-24 中国药科大学 N-取代吲哚羧酸衍生物、其制法及医药用途
US9949965B2 (en) 2014-10-17 2018-04-24 Vanderbilt University Tricyclic indole Mcl-1 inhibitors and uses thereof
WO2016089648A1 (en) 2014-12-01 2016-06-09 Vtv Therapeutics Llc Bach 1 inhibitors in combination with nrf2 activators and pharmaceutical compositions thereof
WO2016109492A1 (en) 2014-12-31 2016-07-07 Angion Biomedica Corp Methods and agents for treating disease
AU2017228385B2 (en) 2016-03-04 2021-11-04 Vanderbilt University Substituted indole Mcl-1 inhibitors
CN105820132B (zh) * 2016-05-12 2018-11-13 广西师范大学 N-芳基苯并三唑类氮氧衍生物及其合成方法
CN105968059B (zh) * 2016-05-12 2018-11-13 广西师范大学 N-烯基苯并三唑类氮氧衍生物及其制备方法和应用
CN111960985A (zh) * 2018-08-08 2020-11-20 中国人民解放军总医院 抗肿瘤化合物
JP2023525047A (ja) 2020-05-06 2023-06-14 エイジャックス セラピューティクス， インコーポレイテッド Ｊａｋ２阻害薬としての６－ヘテロアリールオキシベンゾイミダゾール及びアザベンゾイミダゾール
CN113967210A (zh) * 2020-07-24 2022-01-25 上海交通大学医学院附属瑞金医院 一种干扰整合素β3/Src相互作用的化合物的用途
WO2023086319A1 (en) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. 6-he tero aryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4544670A (en) * 1982-08-24 1985-10-01 William H. Rorer, Inc. Method of treating coccidiosis with acyl guanidines
DE3304019A1 (de) * 1983-02-07 1984-08-09 Kali-Chemie Pharma Gmbh, 3000 Hannover 3-acyloxy-1-phenyl-2-aminocarbonylindol-verbindungen sowie verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE3929582A1 (de) * 1989-09-06 1991-03-07 Hoechst Ag Benzoylguanidine, verfahren zu ihrer herstellung, ihre verwendung als medikament sowie sie enthaltendes medikament
DE4127026A1 (de) * 1991-08-16 1993-02-18 Boehringer Ingelheim Kg Neue pyrazinderivate, ihre herstellung und verwendung

Also Published As

Publication number Publication date
KR950005512A (ko) 1995-03-20
NZ264130A (en) 1995-12-21
NO942864D0 (no) 1994-08-02
AU6884494A (en) 1995-02-16
KR950005817A (ko) 1995-03-20
FI943579A (fi) 1995-02-04
IL110503A0 (en) 1994-10-21
EP0639573A1 (de) 1995-02-22
KR100343292B1 (ko) 2002-12-26
IL110503A (en) 2000-06-29
JPH07145149A (ja) 1995-06-06
HU218790B (hu) 2000-12-28
AU682371B2 (en) 1997-10-02
CA2129301A1 (en) 1995-02-04
HUT70547A (en) 1995-10-30
NO301584B1 (no) 1997-11-17
FI943579A0 (fi) 1994-08-01
HU9402271D0 (en) 1994-09-28
CN1118347A (zh) 1996-03-13

Similar Documents

Publication Publication Date Title
NO942864L (no) Benzokondenserte 5-ringheterocykler, fremgangsmåte for fremstilling derav, deres anvendelse som medikament, deres anvendelse som diagnostikum samt medikament inneholdene disse
NO923466D0 (no) Heterocykliske forbindelser med 5 ledd, fremgangsmaate forfremstilling, samt legemidler som inneholder disse forbindelser
DK654589A (da) Heterocykliske derivater, fremgangsmaade til fremstilling deraf samt farmaceutiske midler indeholdende derivaterne
NO304468B1 (no) 6-leddede nitrogenholdige heteroaryl-oksazolidinoner, anvendelse av disse samt legemiddel inneholdende forbindelsen
NO179911C (no) Optisk aktivt 5H-pyrrolo[3,4-bÅpyrazinderivat samt farmasöytiske preparater inneholdende derivatet
NO944700D0 (no) Nye tienotiazinderivater, fremgangsmåte for fremstilling derav samt farmasöytiske preparater inneholdende forbindelsene
NO304488B1 (no) 5-leddede heteroaryloksazolidinoner, anvendelse av disse for fremstilling av legemidler samt legemiddel inneholdende forbindelsen
NO894270L (no) Synergistisk soetningsmiddel, samt fremgangsmaate for fremstilling av et slikt.
FI940378A0 (fi) 5-jäseniset heterosyklit, menetelmä niiden valmistamiseksi ja näitä yhdisteitä sisältävät lääkeaineet
NO890926D0 (no) Triazolderivater, fremgangsmaate til fremstilling derav samt deres anvendelse som soppdrepende midler.
NO980273D0 (no) Femleddede heterocykluser med bifenylsulfonylsubstitusjon fremgangsmåte for deres fremstilling, deres anvendelse som medikament eller diagnostikum samt medikament inneholdende forbindelsen
DK219387D0 (da) Aminothiazol- og aminooxazolderivater, fremgangsmaade til fremstilling deraf samt farmaceutiske midler indeholdende disse
NO308287B1 (no) Substituerte 4-fenyl-6-amino-nikotinsyrederivater, legemidler inneholdende disse samt deres anvendelse
DK276189D0 (da) Polypeptidforbindelser, fremgangsmaader til fremstilling heraf farmaceutiske midler indeholdende disse
DK378988A (da) Dopamin-beta-hydroxylaseinhibitorer, fremgangsmaade til fremstilling heraf samt farmaceutiske midler indeholdende disse forbindelser
NO902786L (no) Krympeverktoey samt fremgangsmaate for bruk av dette.
NO960364D0 (no) Basisk-substituerte benzolguanidiner, fremgangsmåte for fremstilling derav, deres anvendelse som medikament eller diagnostikum samt medikament inneholdende forbindelsen
DK486789D0 (da) Benzoxazolinonderivater, fremgangsmaader til fremstilling deraf samt farmaceutiske midler indeholdende disse
DK135988A (da) 2,5-dihydropyrroler, fremgangsmaader til deres fremstilling samt deres anvendelse som herbicider
NO985171L (no) Sulfonamidsubstituerte kondenserte 5-ringforbindelser, deres anvendelse som medikament samt farmas°ytiske preparater inneholdende forbindelsene
DK553689A (da) Phenyloxypropanolaminderivater, fremgangsmaade til fremstilling af saadanne forbindelser samt laegemiddel indeholdende disse
NO954739D0 (no) Substituerte benzoylguanidiner, fremgangsmåte for fremstilling derav, deres anvendelse som medikament eller diagnostikum samt medikamenter inneholdende disse forbindelsene
DK266289D0 (da) Alfa-adrenerge receptorantagonister, fremgangsmaader til fremstilling heraf samt farmaceutiske midler indeholdende disse antagonister
NO970140D0 (no) Technetium-sulfonamidkomplekser, deres anvendelse, farmasöytiske midler inneholdende disse, samt fremgangsmåte for fremstilling av kompleksene og midlene
DK165978C (da) 1-aminoethyl-1h-imidazolderivater, fremgangsmaader til fremstilling deraf samt antimykotiske midler indeholdende disse

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees

Free format text: LAPSED IN FEBRUARY 2002